Streetbeat News

AVBP

ArriVent BioPharma Inc.

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

Open

26.71

Mkt cap

892M

Volume

112K

High

27.66

P/E Ratio

-10.15

52-wk high

36.37

Low

26.42

Div yield

N/A

52-wk low

14.35

Biotech and pharmaceutical companies have been significant players in the IPO market, with 24% of IPOs between 2001 and 2023 coming from this sector. The article highlights the best-performing biotech IPO stocks of 2024.

Portfolio Pulse from

November 06, 2024 | 1:45 pm

Citigroup analyst Yigal Nochomovitz has maintained a Buy rating on ArriVent BioPharma and increased the price target from $30 to $36.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 4:18 pm

Oppenheimer analyst Jeff Jones has reiterated an Outperform rating for ArriVent BioPharma (NASDAQ:AVBP) and increased the price target from $35 to $39.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 3:24 pm

Goldman Sachs analyst Corinne Johnson has maintained a Buy rating on ArriVent BioPharma and raised the price target from $28 to $38.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 1:55 pm

HC Wainwright & Co. has maintained a Buy rating on ArriVent BioPharma and increased the price target from $30 to $36, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 11:08 am

ArriVent BioPharma announced positive interim data from its Phase 1b trial of firmonertinib for EGFR PACC mutant NSCLC, showing high response rates. The company will host a webinar to discuss these findings.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 4:07 pm

HC Wainwright & Co. has maintained a Buy rating on ArriVent BioPharma (NASDAQ:AVBP) and raised the price target from $25 to $30.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2024 | 10:42 am

Oppenheimer analyst Jeff Jones has reiterated an Outperform rating on ArriVent BioPharma (NASDAQ:AVBP) and maintained a price target of $35.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 1:53 pm

ArriVent BioPharma (NASDAQ:AVBP) reported a Q2 EPS of $(0.65), missing the analyst consensus estimate of $(0.54) by 20.37%. This represents a significant improvement from the $(10.79) per share loss in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 8:08 pm

ArriVent BioPharma, Inc. (NASDAQ: AVBP) will present interim Phase 1b data for firmonertinib, a treatment for EGFR PACC mutant non-small cell lung cancer, at the 2024 World Conference on Lung Cancer. The presentation will be part of the presidential session, and ArriVent will also host a virtual webinar on September 9, 2024.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 12:10 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.